Veritas In Silico Inc. (JP:130A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Veritas In Silico Inc. has reached a significant milestone in joint drug discovery research with Shionogi & Co., focusing on infectious diseases and psychiatric/neurological disorders. The milestone achievement, part of a collaboration dating back to 2021, will contribute approximately 5% to the company’s 3rd quarter revenue for FY2024, aligning with earlier earnings forecasts. No revisions to the FY2024 earnings forecast are anticipated as a result of this development.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.